JP2022546550A - 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法 - Google Patents

上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法 Download PDF

Info

Publication number
JP2022546550A
JP2022546550A JP2022514172A JP2022514172A JP2022546550A JP 2022546550 A JP2022546550 A JP 2022546550A JP 2022514172 A JP2022514172 A JP 2022514172A JP 2022514172 A JP2022514172 A JP 2022514172A JP 2022546550 A JP2022546550 A JP 2022546550A
Authority
JP
Japan
Prior art keywords
levels
thcy
cbs
patients
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546550A5 (https=
Inventor
セロス－モウラ、マルシア
モシェ バブリル、エレズ
グラビン、フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Switzerland GmbH
Original Assignee
Travere Therapeutics Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Switzerland GmbH filed Critical Travere Therapeutics Switzerland GmbH
Publication of JP2022546550A publication Critical patent/JP2022546550A/ja
Publication of JP2022546550A5 publication Critical patent/JP2022546550A5/ja
Priority to JP2025130469A priority Critical patent/JP2025183204A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
JP2022514172A 2019-09-03 2020-09-03 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法 Pending JP2022546550A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130469A JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895230P 2019-09-03 2019-09-03
US62/895,230 2019-09-03
US202062983862P 2020-03-02 2020-03-02
US62/983,862 2020-03-02
PCT/US2020/049156 WO2021046190A1 (en) 2019-09-03 2020-09-03 Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130469A Division JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Publications (2)

Publication Number Publication Date
JP2022546550A true JP2022546550A (ja) 2022-11-04
JP2022546550A5 JP2022546550A5 (https=) 2023-09-07

Family

ID=74852233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514172A Pending JP2022546550A (ja) 2019-09-03 2020-09-03 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法
JP2025130469A Pending JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130469A Pending JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Country Status (11)

Country Link
US (1) US20220290116A1 (https=)
EP (1) EP4025243A4 (https=)
JP (2) JP2022546550A (https=)
KR (1) KR20220091464A (https=)
CN (1) CN114630673A (https=)
AU (1) AU2020343314A1 (https=)
BR (1) BR112022003539A2 (https=)
CA (1) CA3152379A1 (https=)
IL (1) IL290685A (https=)
MX (1) MX2022002571A (https=)
WO (1) WO2021046190A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3998067T3 (fi) 2015-11-09 2024-10-31 Univ Colorado Regents Koostumukset ja menetelmät homokystinurian hoitoon
IL269544B2 (en) 2017-04-17 2025-01-01 Univ Colorado Regents Streamlining enzyme replacement therapy for the treatment of high homocysteine
ES3058596T3 (en) * 2019-06-26 2026-03-11 Travere Therapeutics Switzerland Gmbh Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506727A (ja) * 2013-01-29 2016-03-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
US20180318404A1 (en) * 2013-01-29 2018-11-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3998067T3 (fi) * 2015-11-09 2024-10-31 Univ Colorado Regents Koostumukset ja menetelmät homokystinurian hoitoon
IL269544B2 (en) * 2017-04-17 2025-01-01 Univ Colorado Regents Streamlining enzyme replacement therapy for the treatment of high homocysteine
ES3058596T3 (en) * 2019-06-26 2026-03-11 Travere Therapeutics Switzerland Gmbh Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506727A (ja) * 2013-01-29 2016-03-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ホモシスチン尿症を処置するためのシスタチオニンβ−シンターゼ酵素
US20180318404A1 (en) * 2013-01-29 2018-11-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J INHERIT METAB DIS, vol. 40, JPN6024027097, 2017, pages 49 - 74, ISSN: 0005366453 *

Also Published As

Publication number Publication date
BR112022003539A2 (pt) 2022-05-24
CA3152379A1 (en) 2021-03-11
AU2020343314A1 (en) 2022-03-24
CN114630673A (zh) 2022-06-14
US20220290116A1 (en) 2022-09-15
MX2022002571A (es) 2022-05-06
IL290685A (en) 2022-04-01
JP2025183204A (ja) 2025-12-16
EP4025243A1 (en) 2022-07-13
KR20220091464A (ko) 2022-06-30
EP4025243A4 (en) 2023-09-27
WO2021046190A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US12364765B2 (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
JP2025183204A (ja) 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法
Pezzini et al. Homocysteine and cerebral ischemia: pathogenic and therapeutical implications
Koyama et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis
Undas et al. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia
Rudolph et al. Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease
BR112020026110A2 (pt) Composições e métodos para o tratamento de hemoglobinopatias e talassemias
Takatsuki et al. IVIG reduced vascular oxidative stress in patients with Kawasaki disease
Rubba et al. Early signs of vascular disease in homocystinuria: a noninvasive study by ultrasound methods in eight families with cystathionine-β-synthase deficiency
Argalious et al. Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery
RU2833879C1 (ru) Терапия с использованием фермента цистатионин-бета-синтазы для лечения заболеваний, вызываемых повышенными уровнями гомоцистеина
RU2839909C2 (ru) Пэгилированная цистатионин-бета-синтаза для ферментотерапии для лечения гомоцистинурии
HK40071277A (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
HK40071277B (en) Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
Roohi et al. Moderately elevated homocysteine does not contribute to thoracic aortic aneurysm in mice
Negreva et al. Paroxysmal atrial fibrillation: dynamics of the main antioxidant enzymes-superoxide dismutase and catalase
Jurcuţ et al. Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age
Zhan et al. Serum angiotensin I-converting enzyme levels and the therapeutic effects of octreotide in esophageal variceal hemorrhage
Taher et al. For the management of non transfusion dependent thalassaemia (ntdt)
Lattanzi et al. ß-Hydroxy-ß-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled Study
Pinna et al. Decreased plasma cysteinylglycine and taurine levels in branch retinal vein occlusion
OA20430A (en) Compositions and methods for the treatment of hemoglobinopathies and thalassemias
Windrum Homocysteine and CVD risk: Is it relevant or redundant?
Franken et al. IS HOMOCYSTEINE-LOWERING TREATMENT BENEFICIAL IN ARTERIOSCLEROSIS DUE TO MILD HYPERHOMOCYSTEINEMIA?
Sabirzhanova et al. Running Title: Rescuing ABCA4 trafficking mutants.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827